Form 4: Tourmaline Bio Director Sells Shares Post-Novartis Merger

Caley Castelein, a Director and 10% Owner of Tourmaline Bio, Inc., reported the disposition of common stock and options following the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Caley Castelein, a Director and 10% Owner of Tourmaline Bio, Inc. (TRML), reported the disposition of securities.
• The transactions occurred on October 28, 2025, pursuant to the Agreement and Plan of Merger with Novartis AG and Torino Merger Sub Inc.
• Merger Sub completed a cash tender offer to acquire all outstanding common stock of Tourmaline Bio for $48.00 in cash per share.
• Castelein disposed of 515,997 shares of common stock held directly.
• An additional 431,939 shares of common stock held indirectly by KVP Capital, LP were also disposed of. Castelein is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP, and disclaims beneficial ownership except for pecuniary interest.
• Employee stock options were also canceled and converted into cash. These included:
• 10,000 options with an exercise price of $9.46.
• 10,000 options with an exercise price of $13.91.
• 16,800 options with an exercise price of $18.73.
• Each option was converted into cash equal to the product of the difference between the $48.00 Merger Consideration and the option's exercise price, multiplied by the number of shares issuable upon exercise.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger where Tourmaline Bio shareholders received $48.00 per share in cash, indicating a positive outcome for investors and the reporting person.

Positives

• The successful completion of the merger provides a clear cash exit for shareholders at $48.00 per share.
• Reporting Person Caley Castelein received significant cash proceeds from the disposition of common stock and the cash-out of stock options.
• The merger consideration of $48.00 per share represents a premium over the option exercise prices, resulting in a positive cash payout for option holders.

Negatives

• Tourmaline Bio, Inc. ceases to be an independent publicly traded entity following the acquisition.
• Shareholders no longer have equity participation in Tourmaline Bio's future growth as an independent company.

Risks

• NA

Future Outlook

The filing indicates the completion of the acquisition of Tourmaline Bio, Inc. by Novartis AG. As a result, Tourmaline Bio is no longer an independent public entity, and its future operations will be integrated under Novartis AG. No specific forward-looking statements for the former Tourmaline Bio are provided.

Industry Context

This transaction represents a consolidation within the biotechnology or pharmaceutical sector, where larger pharmaceutical companies like Novartis AG acquire smaller biotech firms to expand their pipeline or acquire specific technologies/assets. Such acquisitions are common strategies for growth and innovation in the highly competitive life sciences industry.

Related Party Transactions

• Caley Castelein indirectly disposed of 431,939 shares held by KVP Capital, LP. Castelein is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP, indicating a related party relationship for these shares.

Stakeholder Impact

• Shareholders: Received $48.00 per share in cash for their common stock, providing a liquidity event and a defined return on investment.
• Option Holders: Received cash payouts for their vested options, calculated as the difference between the merger consideration and the exercise price.
• Employees (former Tourmaline Bio): While not explicitly detailed, the merger typically leads to integration into the acquiring company, potentially impacting roles and compensation structures.
• Novartis AG: Successfully acquired Tourmaline Bio, expanding its portfolio or strategic assets.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, Form 4, Insider Trading, Stock Disposition, Cash Tender Offer, Caley Castelein, KVP Capital, Employee Stock Options